<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02664922</url>
  </required_header>
  <id_info>
    <org_study_id>Anes Tech 11-003514</org_study_id>
    <nct_id>NCT02664922</nct_id>
  </id_info>
  <brief_title>Anesthetic Techniques in EP Patients</brief_title>
  <official_title>Anesthetic Techniques and the Effect on Cardiac Electrophysiology Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare different combinations of anesthetic drugs (cause&#xD;
      loss of sensation) in terms of effectiveness, adverse effects, pain relief, and patient&#xD;
      comfort for cardiac electrophysiology procedures. In addition, the investigators are studying&#xD;
      the different anesthetic combinations to determine the best approach in terms of&#xD;
      identification and treatment of arrhythmias.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anesthetic management in patients coming for electrophysiology procedures is extremely&#xD;
      important and hemodynamically challenging in order to minimize interference on the&#xD;
      electrophysiology studies (EPS) and the ability to trigger arrhythmias while also maintaining&#xD;
      patient comfort and limited movement. Various anesthetic combinations are administered to&#xD;
      provide sedation, analgesia/sedation, or general anesthesia. The ideal agent should produce&#xD;
      rapid loss of consciousness while ensuring cardiovascular stability and prompt recovery with&#xD;
      few adverse effects. Our goal is to study anesthetic techniques and the effect on&#xD;
      electrophysiology procedures to determine the best anesthetic combination in terms of&#xD;
      effectiveness, adverse effects, pain relief, and patient comfort.&#xD;
&#xD;
      Adult patients scheduled for electrophysiology procedures will be enrolled in the study and&#xD;
      randomly assigned to an anesthetic group based on their schedule procedure. Sedation cases&#xD;
      for supraventricular tachycardia (SVT), right ventricular outflow tract (RVOT)/premature&#xD;
      ventricular contraction (PVC) ablation, and atrial flutter (aflutter) procedures will be&#xD;
      randomly assigned to one of three groups: 1) monitored anesthesia (local anesthesia with&#xD;
      sedation and analgesia/pain reliever) with propofol (induce sleep), 2) monitored anesthesia&#xD;
      with ketamine (sedation) + propofol (induce sleep), or 3) monitored anesthesia with&#xD;
      remifentanil infusion (pain reliever) + propofol (induce sleep). Sedation cases for&#xD;
      ventricular tachycardia (VT) ablation and atrial fibrillation (afib) procedures will be&#xD;
      randomly assigned to one of two groups: 1) monitored anesthesia (local anesthesia with&#xD;
      sedation and analgesia/pain reliever) with propofol (induce sleep), or 2) monitored&#xD;
      anesthesia with ketamine (sedation) + propofol (induce sleep). General anesthesia (GA) cases,&#xD;
      including VT ablation and afib procedures will receive general anesthesia (state of&#xD;
      unconsciousness) with sevoflurane (loss of consciousness) + O2. Anesthesia factors, such as&#xD;
      hemodynamics and cerebral oxygen saturation will be continuously monitored and recorded&#xD;
      throughout the study. In addition, we will be looking at standard echocardiogram and&#xD;
      electrophysiology (EP) parameters. The patient's pain level, level of sedation, and&#xD;
      satisfaction will also be measured using scales, assessments, and surveys.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor study design and too many study groups.&#xD;
  </why_stopped>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of Anesthetic Drugs in Terms of Number of Participants With Adverse Events.</measure>
    <time_frame>Intraoperatively to postoperatively in the ICU, an expected average of 5-7 hours.</time_frame>
    <description>Direct observation and medical record review will be used to analyze adverse effects. Reported as number of participants with one or more adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness of Anesthetic Drugs in Terms of Pain Relief.</measure>
    <time_frame>Intraoperatively to postoperatively in the ICU, an expected average of 5-7 hours.</time_frame>
    <description>A patient's pain level will be assessed using a numerical pain rating scale from 0 &quot;no pain&quot; to 10 &quot;worst possible pain&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness of Anesthetic Drugs in Terms of Patient Comfort.</measure>
    <time_frame>Intraoperatively to postoperatively in the ICU, an expected average of 5-7 hours.</time_frame>
    <description>A patient's level of sedation will be assessed using a scoring system on a scale from 1-5. The Observer's Assessment of Alertness/Sedation (OAA/S) Score Responsiveness Component score from 1 - Does not respond to mild prodding or shaking to 5 - Responds readily to name spoken in normal tone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness of Anesthetic Drugs in Terms of Patient Satisfaction.</measure>
    <time_frame>Intraoperatively to postoperatively in the ICU, an expected average of 5-7 hours.</time_frame>
    <description>Patients will also be asked to complete a written questionnaire prior to discharge from the hospital to measure patient satisfaction during their anesthesia care. A Likert Scale is used and ranges from 1 - Disagree very much to 6 - Agree very much.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of Anesthetic Drugs in Terms of Proceduralist Satisfaction.</measure>
    <time_frame>Intraoperatively to postoperatively in the ICU, an expected average of 5-7 hours.</time_frame>
    <description>The proceduralist will complete a written questionnaire after the procedure to rate their satisfaction. A Likert Scale is used and ranges from 1 - Disagree very much to 6 - Agree very much.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of Anesthetic Drugs in Terms of Number of Participants With Clinical Success.</measure>
    <time_frame>1-3 months postoperatively</time_frame>
    <description>The proceduralist will follow-up 1-3 months post-procedure to evaluate the number of participants with clinical success reported by number of recurrences. Clinical success is defined as 0 recurrences in participants at 1-3 months post-operatively.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Cardiac Disease</condition>
  <arm_group>
    <arm_group_label>Sedation - Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sedation - monitored anesthesia with propofol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sedation - Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sedation - monitored anesthesia with ketamine + propofol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sedation - Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sedation - monitored anesthesia with remifentanil + propofol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>General Anesthesia - Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>General anesthesia (GA) with Sevoflurane + O2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
    <arm_group_label>Sedation - Group 1</arm_group_label>
    <arm_group_label>Sedation - Group 2</arm_group_label>
    <arm_group_label>Sedation - Group 3</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
    <arm_group_label>Sedation - Group 2</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.</description>
    <arm_group_label>Sedation - Group 3</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>1 general anesthesia group for VT ablations and afib procedures.</description>
    <arm_group_label>General Anesthesia - Group 1</arm_group_label>
    <other_name>Ultane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for cardiac electrophysiology procedures&#xD;
&#xD;
          -  Patients ≥18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gastroesophageal reflux disease (GERD),&#xD;
&#xD;
          -  pulmonary hypertension,&#xD;
&#xD;
          -  severe pulmonary disease,&#xD;
&#xD;
          -  obstructive sleep apnea (OSA) with continuous positive airway pressure therapy (CPAP)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aman Mahajan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 5, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2016</study_first_posted>
  <results_first_submitted>September 3, 2020</results_first_submitted>
  <results_first_submitted_qc>September 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 22, 2020</results_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electrophysiology</keyword>
  <keyword>Anesthetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sedation - Group 1</title>
          <description>Sedation - monitored anesthesia with propofol.&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
        </group>
        <group group_id="P2">
          <title>Sedation - Group 2</title>
          <description>Sedation - monitored anesthesia with ketamine + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Ketamine: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
        </group>
        <group group_id="P3">
          <title>Sedation - Group 3</title>
          <description>Sedation - monitored anesthesia with remifentanil + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Remifentanil: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.</description>
        </group>
        <group group_id="P4">
          <title>General Anesthesia - Group 1</title>
          <description>General anesthesia (GA) with Sevoflurane + O2&#xD;
Sevoflurane: 1 general anesthesia group for VT ablations and afib procedures.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sedation - Group 1</title>
          <description>Sedation - monitored anesthesia with propofol.&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
        </group>
        <group group_id="B2">
          <title>Sedation - Group 2</title>
          <description>Sedation - monitored anesthesia with ketamine + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Ketamine: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
        </group>
        <group group_id="B3">
          <title>Sedation - Group 3</title>
          <description>Sedation - monitored anesthesia with remifentanil + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Remifentanil: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.</description>
        </group>
        <group group_id="B4">
          <title>General Anesthesia - Group 1</title>
          <description>General anesthesia (GA) with Sevoflurane + O2&#xD;
Sevoflurane: 1 general anesthesia group for VT ablations and afib procedures.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="16"/>
                    <measurement group_id="B2" value="56" spread="13"/>
                    <measurement group_id="B3" value="48" spread="18"/>
                    <measurement group_id="B4" value="43" spread="16"/>
                    <measurement group_id="B5" value="53" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness of Anesthetic Drugs in Terms of Number of Participants With Adverse Events.</title>
        <description>Direct observation and medical record review will be used to analyze adverse effects. Reported as number of participants with one or more adverse events.</description>
        <time_frame>Intraoperatively to postoperatively in the ICU, an expected average of 5-7 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sedation - Group 1</title>
            <description>Sedation - monitored anesthesia with propofol.&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
          </group>
          <group group_id="O2">
            <title>Sedation - Group 2</title>
            <description>Sedation - monitored anesthesia with ketamine + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Ketamine: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
          </group>
          <group group_id="O3">
            <title>Sedation - Group 3</title>
            <description>Sedation - monitored anesthesia with remifentanil + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Remifentanil: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.</description>
          </group>
          <group group_id="O4">
            <title>General Anesthesia - Group 1</title>
            <description>General anesthesia (GA) with Sevoflurane + O2&#xD;
Sevoflurane: 1 general anesthesia group for VT ablations and afib procedures.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness of Anesthetic Drugs in Terms of Number of Participants With Adverse Events.</title>
          <description>Direct observation and medical record review will be used to analyze adverse effects. Reported as number of participants with one or more adverse events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness of Anesthetic Drugs in Terms of Pain Relief.</title>
        <description>A patient's pain level will be assessed using a numerical pain rating scale from 0 &quot;no pain&quot; to 10 &quot;worst possible pain&quot;.</description>
        <time_frame>Intraoperatively to postoperatively in the ICU, an expected average of 5-7 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sedation - Group 1</title>
            <description>Sedation - monitored anesthesia with propofol.&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
          </group>
          <group group_id="O2">
            <title>Sedation - Group 2</title>
            <description>Sedation - monitored anesthesia with ketamine + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Ketamine: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
          </group>
          <group group_id="O3">
            <title>Sedation - Group 3</title>
            <description>Sedation - monitored anesthesia with remifentanil + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Remifentanil: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.</description>
          </group>
          <group group_id="O4">
            <title>General Anesthesia - Group 1</title>
            <description>General anesthesia (GA) with Sevoflurane + O2&#xD;
Sevoflurane: 1 general anesthesia group for VT ablations and afib procedures.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness of Anesthetic Drugs in Terms of Pain Relief.</title>
          <description>A patient's pain level will be assessed using a numerical pain rating scale from 0 &quot;no pain&quot; to 10 &quot;worst possible pain&quot;.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.3"/>
                    <measurement group_id="O2" value="0.4" spread="0.5"/>
                    <measurement group_id="O3" value="0.2" spread="0.5"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness of Anesthetic Drugs in Terms of Patient Comfort.</title>
        <description>A patient's level of sedation will be assessed using a scoring system on a scale from 1-5. The Observer's Assessment of Alertness/Sedation (OAA/S) Score Responsiveness Component score from 1 - Does not respond to mild prodding or shaking to 5 - Responds readily to name spoken in normal tone.</description>
        <time_frame>Intraoperatively to postoperatively in the ICU, an expected average of 5-7 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sedation - Group 1</title>
            <description>Sedation - monitored anesthesia with propofol.&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
          </group>
          <group group_id="O2">
            <title>Sedation - Group 2</title>
            <description>Sedation - monitored anesthesia with ketamine + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Ketamine: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
          </group>
          <group group_id="O3">
            <title>Sedation - Group 3</title>
            <description>Sedation - monitored anesthesia with remifentanil + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Remifentanil: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.</description>
          </group>
          <group group_id="O4">
            <title>General Anesthesia - Group 1</title>
            <description>General anesthesia (GA) with Sevoflurane + O2&#xD;
Sevoflurane: 1 general anesthesia group for VT ablations and afib procedures.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness of Anesthetic Drugs in Terms of Patient Comfort.</title>
          <description>A patient's level of sedation will be assessed using a scoring system on a scale from 1-5. The Observer's Assessment of Alertness/Sedation (OAA/S) Score Responsiveness Component score from 1 - Does not respond to mild prodding or shaking to 5 - Responds readily to name spoken in normal tone.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.2"/>
                    <measurement group_id="O2" value="3.0" spread="1.3"/>
                    <measurement group_id="O3" value="3.0" spread="1.3"/>
                    <measurement group_id="O4" value="1.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness of Anesthetic Drugs in Terms of Patient Satisfaction.</title>
        <description>Patients will also be asked to complete a written questionnaire prior to discharge from the hospital to measure patient satisfaction during their anesthesia care. A Likert Scale is used and ranges from 1 - Disagree very much to 6 - Agree very much.</description>
        <time_frame>Intraoperatively to postoperatively in the ICU, an expected average of 5-7 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sedation - Group 1</title>
            <description>Sedation - monitored anesthesia with propofol.&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
          </group>
          <group group_id="O2">
            <title>Sedation - Group 2</title>
            <description>Sedation - monitored anesthesia with ketamine + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Ketamine: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
          </group>
          <group group_id="O3">
            <title>Sedation - Group 3</title>
            <description>Sedation - monitored anesthesia with remifentanil + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Remifentanil: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.</description>
          </group>
          <group group_id="O4">
            <title>General Anesthesia - Group 1</title>
            <description>General anesthesia (GA) with Sevoflurane + O2&#xD;
Sevoflurane: 1 general anesthesia group for VT ablations and afib procedures.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness of Anesthetic Drugs in Terms of Patient Satisfaction.</title>
          <description>Patients will also be asked to complete a written questionnaire prior to discharge from the hospital to measure patient satisfaction during their anesthesia care. A Likert Scale is used and ranges from 1 - Disagree very much to 6 - Agree very much.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.4"/>
                    <measurement group_id="O2" value="3.0" spread="0.7"/>
                    <measurement group_id="O3" value="3.5" spread="0.5"/>
                    <measurement group_id="O4" value="3.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effectiveness of Anesthetic Drugs in Terms of Proceduralist Satisfaction.</title>
        <description>The proceduralist will complete a written questionnaire after the procedure to rate their satisfaction. A Likert Scale is used and ranges from 1 - Disagree very much to 6 - Agree very much.</description>
        <time_frame>Intraoperatively to postoperatively in the ICU, an expected average of 5-7 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sedation - Group 1</title>
            <description>Sedation - monitored anesthesia with propofol.&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
          </group>
          <group group_id="O2">
            <title>Sedation - Group 2</title>
            <description>Sedation - monitored anesthesia with ketamine + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Ketamine: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
          </group>
          <group group_id="O3">
            <title>Sedation - Group 3</title>
            <description>Sedation - monitored anesthesia with remifentanil + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Remifentanil: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.</description>
          </group>
          <group group_id="O4">
            <title>General Anesthesia - Group 1</title>
            <description>General anesthesia (GA) with Sevoflurane + O2&#xD;
Sevoflurane: 1 general anesthesia group for VT ablations and afib procedures.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness of Anesthetic Drugs in Terms of Proceduralist Satisfaction.</title>
          <description>The proceduralist will complete a written questionnaire after the procedure to rate their satisfaction. A Likert Scale is used and ranges from 1 - Disagree very much to 6 - Agree very much.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="0.4"/>
                    <measurement group_id="O2" value="5.6" spread="0.5"/>
                    <measurement group_id="O3" value="5.2" spread="0.3"/>
                    <measurement group_id="O4" value="5.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effectiveness of Anesthetic Drugs in Terms of Number of Participants With Clinical Success.</title>
        <description>The proceduralist will follow-up 1-3 months post-procedure to evaluate the number of participants with clinical success reported by number of recurrences. Clinical success is defined as 0 recurrences in participants at 1-3 months post-operatively.</description>
        <time_frame>1-3 months postoperatively</time_frame>
        <population>Patients were excluded from analysis if there was no electrophysiology follow-up in the medical record 1-3 months postoperatively.</population>
        <group_list>
          <group group_id="O1">
            <title>Sedation - Group 1</title>
            <description>Sedation - monitored anesthesia with propofol.&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
          </group>
          <group group_id="O2">
            <title>Sedation - Group 2</title>
            <description>Sedation - monitored anesthesia with ketamine + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Ketamine: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
          </group>
          <group group_id="O3">
            <title>Sedation - Group 3</title>
            <description>Sedation - monitored anesthesia with remifentanil + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Remifentanil: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.</description>
          </group>
          <group group_id="O4">
            <title>General Anesthesia - Group 1</title>
            <description>General anesthesia (GA) with Sevoflurane + O2&#xD;
Sevoflurane: 1 general anesthesia group for VT ablations and afib procedures.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness of Anesthetic Drugs in Terms of Number of Participants With Clinical Success.</title>
          <description>The proceduralist will follow-up 1-3 months post-procedure to evaluate the number of participants with clinical success reported by number of recurrences. Clinical success is defined as 0 recurrences in participants at 1-3 months post-operatively.</description>
          <population>Patients were excluded from analysis if there was no electrophysiology follow-up in the medical record 1-3 months postoperatively.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Intraoperatively to postoperatively in the ICU, an expected average of 5-7 hours, and up to 5 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sedation - Group 1</title>
          <description>Sedation - monitored anesthesia with propofol.&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
        </group>
        <group group_id="E2">
          <title>Sedation - Group 2</title>
          <description>Sedation - monitored anesthesia with ketamine + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Ketamine: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.</description>
        </group>
        <group group_id="E3">
          <title>Sedation - Group 3</title>
          <description>Sedation - monitored anesthesia with remifentanil + propofol&#xD;
Propofol: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.&#xD;
1 of 2 sedation groups for VT ablation and afib procedures.&#xD;
Remifentanil: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.</description>
        </group>
        <group group_id="E4">
          <title>General Anesthesia - Group 1</title>
          <description>General anesthesia (GA) with Sevoflurane + O2&#xD;
Sevoflurane: 1 general anesthesia group for VT ablations and afib procedures.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>New onset atrial fibrillation requiring cardioversion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>VA ECMO</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Multiorgan Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>slow ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>non-sustained ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pericardial Drain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Scovotti</name_or_title>
      <organization>University of California, Los Angeles</organization>
      <phone>310.206.4484</phone>
      <email>jscovotti@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

